PATENT CLAIM ANALYSIS

Application Number: 15933098
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "210010"]

Abstract:
The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8  are defined herein.

Claim (Index 81):
The compound of  claim 62 , wherein R 1  is not cyclopentane.

Metadata:
- Claim Count in Document: 95.0
- Percentile: 90.0
- Lexical Diversity: 1.63077
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14759385', '14782308', '15886766', '13126490', '14423963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.775929941702573
- 35 USC 102 Novelty (BERT): 0.5400574224097242
- Combined Prediction Score: 0.7523426897732881
- Mean Citation Score: 298.000968
- Max Citation Score: 378.1172
- Similarity Product: 263.61154735157487

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test